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Abstract The role of genetic background in childhood-onset
combined pituitary hormone deficiency (CPHD) has been ex-
tensively studied. The major contributors are the PROP1,
POU1F1, LHX3, LHX4 and HESX1 genes coding transcrip-
tion factors implicated in pituitary organogenesis. The clinical
consequences of mutations encompass impaired synthesis of a
growth hormone (GH) and one or more concurrent pituitary
hormones (i.e. LH, FSH, TSH, PRL). Manifestation of the
disorder may vary due to various mutation impacts on the final
gene products or an influence of environmental factors during
pituitary organogenesis. We describe the clinical and molecu-
lar characteristics of two brothers aged 47 and 39 years pre-
senting an uncommon manifestation of congenital hypopitu-
itarism. Sequencing of the PROP1, POU1F1, LHX3, LHX4
andHESX1 genes was performed to confirm the genetic origin
of the disorder. A compound heterozygosity in the PROP1
gene has been identified for both probands. The first change
represents a mutational hot spot (c.150delA, p.R53fsX164),
whereas the second is a novel alteration (p.R112X) that leads
to protein disruption. Based on precise genetic diagnosis, an in
silico prediction of a p.R112X mutation on protein architec-
ture was performed. The resulting clinical phenotype was sur-
prisingly distinct compared to most patients with genetic al-
terations in PROP1 reported in the current literature. This may
be caused by a residual activity of a newly identified p.R112X
protein that preserves over 70 % of the homeodomain struc-
ture. This examination may confirm a key role of a DNA-
binding homeodomain in maintaining PROP1 functionality
and suggests a conceivable explanation of an unusual
phenotype.
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Introduction
Intensive studies of pituitary organogenesis revealed the indis-
putable role of transcription factors genes defects in the devel-
opment of familial combined pituitary hormone deficiency
(CPHD). Several mutations have been described within
HESX1, LHX3, LHX4, PROP1, POU1F1, PTX and other
genes (Romero et al. 2011). Small recurring deletions in the
PROP1 gene coding transcription factor taking part in the
regulation of pituitary organogenesis are the most common
cause of genetically determined CPHD (Böttner et al. 2004;
Lebl et al. 2005; Lemos et al. 2006; Voutetakis et al. 2004a).
The gene is composed of three highly conserved exons that
code for the protein of 226 amino acids residues, retaining the
abilities of DNA binding and transcriptional activation
(Sornson et al. 1996). Most of these mutations are located
within the second exon of the PROP1 gene, although there
are some variations ofmutations patterns reported for different
populations (Kim et al. 2003; McLennan et al. 2003). In more
than half of familial CPHD cases, PROP1 gene mutations
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have been identified (Deladoëy et al. 1999). The most com-
mon mutation is 301-302delAG and the second is 150delA;
other mutations are less frequent. Noticeably lower common
frequency of these mutational hot spots was detected among
sporadic patients (Turton et al. 2005), supporting the theory of
a founder effect mechanism instead of its de novo nature.
PROP1 gene mutations lead to hypopituitarism that is
characterised by insufficiency of growth hormone (GH), lu-
teinising hormone (LH), follicle-stimulating hormone (FSH)
and thyroid-stimulating hormone (TSH) synthesis and release.
Usually, the first noted symptom is growth failure, and the
observed onset encompasses 2 to 8 years of age. The mani-
festation of central hypothyroidism appears in varying de-
grees. Typically, in the second decade of life, no sexual mat-
uration is evident and the genitals remain infantile. In some
cases of CPHD, usually in the second or even third decades of
life, secondary adrenocortical failure develops or a selective
DHEA deficiency is seen with normal ACTH–cortisol axis
function. In parallel, prolactin deficiency might be present
(Flück et al. 1998; Mody et al. 2002; Voutetakis et al. 2001).
The aim of the present work was to evaluate the genetic
background of CPHD in two brothers with unusual manifes-
tation of a disorder and to describe the uncommon phenotype.
Patients and methods
Patients
Patient 1 was born to parents of normal height after a full-term
pregnancy without any complications; his physical and mental
development was normal in the first 5 years of life without
marked growth disturbances [−1.0 standard deviation (SD)].
When the patient was 6 years old, his parents noted growth
deficiency, pallor of the skin and marked facial oedema. The
paediatrician suspected hypothyroidism that was seemingly
supported by hypercholesterolaemia and lowered serum thy-
roid hormone concentrations: total T4 was 0.8 μg/dL (normal
range: 4–12) and total T3 was 76 ng/dL (normal range: 80–
200). At that time, analysis of the TSH concentration was not
available. The paediatrician commenced levothyroxine thera-
py. Following this treatment, the patient showed improvement
and oedema regressed; however, the linear growth rate was
deficient (−2.7 SD). His mental development was normal and
he had no learning difficulties at school. At the late age of
puberty, signs of sexual maturation were not present and the
patient was referred to the Department of Endocrinology,
where, based on the hormonal test results, a diagnosis of
childhood-onset CPHD (deficiency of GH, TSH and LH/
FSH) was made. At that time, computed tomography (CT)
scan of the pituitary area revealed the presence of a
hyperdense mass (the density of which did not increase after
contrast administration) in a markedly enlarged sella. That
lesion was surrounded by fluid. Magnetic resonance imaging
(MRI) performed during the next medical evaluation (12 years
later) showed remnants of the pituitary gland with a height of
about 5–6 mm and a hypodense lesion (about 6 mm in diam-
eter) between the anterior and posterior lobes not enhanced
with contrast and localised at the left side of the gland. The
patient was treated with long-acting testosterone derivatives
and levothyroxine (treatment with growth hormone was not
available at that moment). He felt well and his growth rate
slowly advanced. even in the third decade of life. At the age
of 34 years, radiograms of the hands, hips and femurs revealed
that epiphyseal fusion did not occur.
Patient 2 was born 8 years after patient 1. At birth, his
weight, length and body proportions were normal. His phys-
ical and mental development, in the first four years of life, had
a normal course. When he was 4 years old, a mild slowing of
the growth rate was noticed (−1.5 SD); the stunted growth was
more evident when the patient started his school education at
the age of 7 years (−2.0 SD). He was referred to the paedia-
trician who, in the case history, described skin dryness, puff-
iness of the face and extremities, increased cholesterol level in
the blood and diagnosed hypothyroidism, suspecting a similar
problem as in the case of his older brother. The detailed
information about his hormone levels at that moment was
not available to us. The patient was then treated with
levo thyrox ine and anabo l i c s t e ro id medica t ion
(methandienone, 5 mg daily) to stimulate the stunted growth.
This therapy was irregularly continued for several years and
resulted in improvement of the patient; however, signs of sex-
ual maturation did not appear and his growth was still defi-
cient (−2.1 SD). At 15 years of age, he was intermittently
treated with testosterone enanthate 100 mg intra-muscularly
every 2 weeks and 100 μg of levothyroxine daily for several
years, resulting in slow linear growth rate (even past the age of
20 years), but only slight sexual improvement.
Both brothers were treated and remained under the control
of a local endocrinologist. The serum hormone levels were re-
evaluated at ages of 47 years for patient 1 and 39 years for
patient 2, when they were referred to the Department of
Endocrinology, Metabolism and Internal Diseases, Poznan
University of Medical Sciences, Poland to establish the treat-
ment direction after a long period of irregular hormone re-
placement therapy.
Hormonal assays and tests
On the patients’ re-evaluations, the basal and stimulated serum
GH levels were measured by an immunoradiometric assay
(IRMA; DSL Inc., Webster, TX, USA). The GH response in
each patient was assessed during insulin-induced
hypoglycaemia (0,1 IU/kg; Actrapid insulin, Novo Nordisk,
Denmark). The serum IGF-1 concentration was estimated
using SM-C-RIA-CT kits (BioSource, Nivelles, Belgium).
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TSH, fT4, prolactin, cortisol, DHEA-S, LH, FSH and insulin
were measured by an immunochemiluminometric assay
(ICMA; Roche Diagnostics Elecsys 2010, Basel,
Switzerland). The serum ACTH level was assessed by
immunoradiometric assay (B.R.A.H.M.S., Hennigsdorf,
Germany) and free testosterone was evaluated using RIA kits
(DPC, Monroe, LA, USA). The pituitary–adrenal axis was
evaluated using insulin-induced hypoglycaemia according to
standard procedures, considering normal adrenal response
when the cortisol level was over 550 nmol/L. Beside basic
levels, TSH and prolactin were also estimated in the TRH
stimulation test (200 μg Protirelin i.v., Merck, Darmstadt,
Germany). The LH/FSH response was investigated using the
GnRH test (100 μg GnRH, Ferring, Germany).
Radiological imaging
PituitaryMRI was performed using the spin-echo technique in
T1-weighted coronal and sagittal scans. Patient 1’s sagittal T1-
weighted pituitary images were performed with a Siemens
MAGNETOM Avanto and acquired using multi-slice spin-
echo pulse sequences with parameters of 800/15/4 (TR/TE/
excitations), 3-mm slice thickness with 1-mm interslice gap,
256×256 acquisition matrix and a 24-cm field of view. Scans
for patient 2 were performed with a Siemens 1T
MAGNETOM Impact using multi-slice spin-echo pulse se-
quences with 500/12/4 (TR/TE/excitations), 3-mm slice thick-
ness with 1-mm interslice gap and a 184×210 acquisition
matrix. Coronal T1-weighted images were also obtained with
a field of view of 20 cm for both patients. Radiograms of the
skull were evaluated in the sagittal and coronal planes, with
the sella turcica length measurement expressed as a distance
from the tuberculum sellae to the posterior clinoid (Andredaki
et al. 2007).
Molecular screening of CPHD genes
Blood samples were collected from both brothers. Genomic
DNAwas extracted from peripheral blood leukocytes accord-
ing to standard procedures (GTC method). Mutation scanning
was carried out by polymerase chain reaction (PCR) and fol-
lowing sequencing of the PCR products. The entire coding
sequence of PROP1, POU1F1, LHX3 and LHX4 was ampli-
fied, as well as neighbouring exons’ intronic sequences
(at least 50 nucleotides of each intron–exon boundary). The
sequence of PROP1 primers for PCR reaction was used ac-
cording to those previously published: for the first exon by
Deladoëy et al. (1999) and for the second exon by
Rosenbloom et al. (1999). For the third exon, a nested PCR
was utilised with a new primer pair that was designed on the
basis of the PROP1 genomic sequence. Primer sequences for
POU1F1, LHX3, LHX4 and HESX1 were designed using the
Primer3 algorithm (http://bioinfo.ut.ee/primer3-0.4.0/).
Genomic sequences for all mentioned genes were recovered
from GeeBank. All primer sequences for PCR are given in
Table 1.
Amplifications were conducted with the use of the
FailSafe™ PCR PreMix J System (Epicentre, Illumina) and
processed through 35 cycles (30 s at 94 °C, 30 s at 62 °C and
45 s at 72 °C). All fragments were then subjected to Sanger
sequencing on both strands. Capillary sequencing was con-
ducted with the use of BigDye chemistry version 3.1 on an
ABI 3130xl DNA Analyzer, according to the manufacturer’s
instructions (Applied Biosystems, Foster City, CA, USA).
Samples were processed through 30 cycles of amplification
consisting of 30 s at 94 °C, 30 s at 60 °C and 45 s at 72 °C. The
final step was lengthened to 7 min.
Analysis of sequence tracks was achieved with the use of
CodonCode Aligner software version 4.0.4 (http://www.
codoncode.com). Patients were also screened for structural
rearrangements in the PROP1, POU1F1, LHX3, LHX4,
HESX1 and, additionally, GH1 and GHRHR genes using the
multiplex ligation-dependent probe amplification (MLPA)
method. MLPA reaction was performed using SALSA
MLPA P216 Growth Hormone Deficiency mix −1 from
MRC-Holland (Netherlands), according to the manufacturer’s
instructions. This kit contains probes for all exons of the men-
tioned genes except for exon 2 of GH1, exon 5 of POU1F1
and exon 8 of GHRHR. The amount of genomic DNA used
for the MLPA analysis was 200 ng. PCR products were sep-
arated on an ABI 3130xl Capillary Sequencer (Applied
Biosystems). Data were normalised intra-sample by dividing
the peak area of each probe’s amplification product by the
total area of only the reference probes in the probemix.
Intra-sample normalisation was achieved by dividing the
intra-normalised probe ratio of all reference samples. Data
normalisation was performed within one experiment (MRC-
Holland). Peak areas in the range 0.7–1.3 are normal, below 0.
7 is considered as one copy deletion and above 1.3 for dupli-
cation. Each MLPA analysis included several control samples
(DNA from healthy individuals).
Bioinformatics approaches
The identified mutations were checked for correctness of po-
sition assessment with the use of theMutationTaster2 program
(Schwarz et al. 2010). By employing Bayes classifiers,
MutationTaster2 facilitates prediction of the pathogenicity
for an alteration, possible impact of nonsense-mediated decay
(NMD) and search for reported variations in the region of
novel mutation within selected databases [dbSNP/TGP/
HGMD(public)/ClinVar]. Computation of the PROP1
homeodomain was conveyed with the use of SWISS-
MODEL (Schwede et al. 2003) and Phyre2 (Kelley and
Sternberg 2009), including ten flanking amino acids from both
ends. The results were than subsequently compared and
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evaluated. Confidence in the models was as follows: 78 resi-
dues (98 %) modelled at >90 % accuracy for the reference
homeodomain and 50 residues (96 %) modelled at >90 %
accuracy for the p.R112X homeodomain. The protein struc-
tures (pdb files) were subjected to molecular graphics and
further analyses with the use of the UCSF Chimera package
(Pettersen et al. 2004; Yang et al. 2012).
Results
Both patients were admitted to the Department of
Endocrinology, Poznan University of Medical Sciences after
irregular therapy with L-thyroxine and testosterone enanthate
for hormonal re-evaluation and imaging study. On physical
examination of the 47-year-old patient 1, his height was
152 cm (−4.0 SD), body proportions normal and his arm span
measured 152 cm. He was obese [body mass index (BMI)
30.2 kg/m2]. His head circumference (measured just above
the ears and eyebrows level) was 58 cm (75th percentile), face
was pale and bloated with puffed upper eyelids and cheeks,
and his nose was broad. His skin was dry, muscles poorly
developed and subcutaneous fat tissue was abundant, espe-
cially on the abdomen obscuring the waist; fat pads were also
present in the supraclavicular areas. There was no beard
growth and no body hair, the axillary and pubic and scrotum
hair were scanty. His genitals were underdeveloped, the penis
and testicles of child-like proportions and his scrotum was
Table 1 Primer sequences used for PROP1, POU1F1, LHX3, LHX4 and HESX1 screening
Genomic sequence: hg19_chr5:177418235-177424243_rev
PROP1 Left primer Right primer Product size
Exon1 TTCAGAGACAGAGTCCCAGA CTCCTAACCTTCTTCATGGA 326
Exon2 TGGTCCAGCACCGAGAG TGCCCAACATTCTATGATAGC 366
Exon3a TCTGGCCATGCTGGAGAAG TTCTAATCGCTGAGCTGAC 579
Exon3b (nested) CCCTGCACCTCTTGTCATTGGAGT AAGCCACCCCATTTTCTTGTCTTT 492
Genomic sequence: hg19_chr3:87307782-87326737_rev
POU1F1 Left primer Right primer Product size
Exon1 ATTGAATCGGCCCTTTGAG GGGTAAAATGAAAGATGCAAAG 334
Exon2 CCTACTCGTCAGAGAACTTACCC TCTGATCACAATTCTTTCAGGC 358
Exon3 TGGGCTAAGTCAGGCAAAAC TCCATAACGACTAACTACGTCCAC 454
Exon4 CAGATTTGTGTGACAATGAACC AAAACCCCTCAAACCTCCTG 342
Exon5 CATTCCAACAAAAGTAAAGTGAGG CTGGGATTATAGGCACCCAC 538
Exon6 TGTCCTGCAAGTGTGTTCAG TGTGAGAAAGAGAGCGGGAG 632
Genomic sequence: hg19_chr9:139087095-139097955_rev
LHX3 Left primer Right primer Product size
Exon1 CTCCAGGGGACGCTGAC ACTTTCTTTGCCTGGCCG 234
Exon2 AAGGTGGCTTCACTGCCTC CTTGGTGATTGTGAGGGGAG 310
Exon3 GCTCGGGGCGAAATGAG GGAGAGAATTTCCCCGGAC 354
Exon4/5 CCTTCCGAGAAGCCTGTG TCCATGGGAAATTCAGATCC 642
Exon6 CAGGATGGGACTCTGAGGG CCTGGCCCCACTTCCTC 580
Genomic sequence: hg19_chr1:180198432-18024518
LHX4 Left primer Right primer Product size
Exon1 AGCTAGAGCGAGAGAGCGAG CCCTGTGACCGCCTCTG 268
Exon2 TGGTTAGCAGGGCTGTGTG CTCACTGCTTGGGGAGAGG 289
Exon3 GAAGCCAGATCCCTTGCTC GAGAAGGGCACCTCAGGC 335
Exon4 AGGGTGTGGGAGGAGGC TCACTCAGGATACCTTCCACC 295
Exon5 GCTTTGGGTTTGTGGTGG TCCTGAGTGCCAGGGATTAC 302
Exon6 GGGACCATCAGAGTCCTGG TTCGATCCTTAAAAGGCAAG 535
Genomic sequence: hg19_chr3:57230943-57235280_rev
HESX Left primer Right primer Product size
Exon1 CCTATACACGTGGGGCAGAG TGAAATAAAGGGCAAATTAAACAC 290
Exon2 TCCTGAAACTACCTCTATAGAACTTTG TGCTCAACTTGGTGTCAATTAAAG 339
Exon3/4 AGACTACCATATTTTAACAATTTCCAG CACTGATTCTTCATGCTCTGC 498
376 J Appl Genetics (2016) 57:373–381
only slightly pigmented (Tanner stage 2). The results of the
hormone assays are listed in Table 2.
Patient 2 was admitted for detailed hormonal investigations
when he was 39 years old. On physical examination, his
height was 161 cm (−2.88 SD) and his weight was 65 kg.
His body proportions were normal. with an arm span of
161 cm. His head circumference (measured as above) was
59 cm (over the 90th percentile), and the patient did not pres-
ent child-like proportions between the vault and face; also, his
nose was broad and well developed. His skin was dry, and a
slight puffiness was seen on his face and dorsum of the hands.
There was no beard growth and sexual hair was scanty. The
size of his genitals was like in the pre-pubertal stage (Tanner
stage 1) and bilateral cryptorchidism was present.
Lateral skull radiography performed in both brothers re-
vealed thick calvarial bones. The sella was rounded and of
increased dimensions (the sella length in patient 1 was
15 mm and that in patient 2 was 14 mm). The dorsum had a
vertical position, with no posterior clinoid processes.
MRI findings
Patient 1
Pituitary scans revealed a discrete deepening of the sella and
reduced mass of the anterior lobe due to the presence of a cyst
on the left side with dimensions 6 × 5 × 7 mm. All pituitary
masses had dimensions as follows: height 5–6 mm, width
(coronal plane) 13 mm and anteroposterior 12 mm. There
was no posterior lobe ectopy or pituitary stalk interruption,
although the stalk appeared to be thin (1–2 mm) (Fig. 1).
Patient 2
MRI scans revealed pituitary hypoplasia with height 2 mm,
width (coronal plane) 11–12 mm and anteroposterior dimen-
sion 10 mm. Like in patient 1, there was no dislocation of the
posterior lobe and no interruption of the pituitary stalk
(Fig. 2).
Table 2 Individual blood hormone values in the two studied patients
before and after stimulation tests performed during the last hospitalisation
(patient 1 at age 47 years and patient 2 at age 39 years)
Hormone Patient 1 Patient 2 Normal range*
(basal evaluation)
Basal Peak Basal Peak
GH (ng/mL) 1.1 1.3 0.5 1.3 0–10
IGF-1 (ng/mL) 23 – 56 – 90–412
TSH (mIU/L) 0.2 2.1 0.14 1.9 0.27–4.2
fT4 (pmol/L) 6.5 – 7.1 – 11.5–21.0
LH (mIU/mL) 0.1 1.6 0.1 1.8 1.5–9.0
FSH (mIU/mL) 0.1 1.9 0.1 1.7 1.5–12.5
Testosterone (pg/mL) 2,3 – 4,8 – 5.6–27.0
ACTH (pg/mL) 23.0 59.7 18.1 39.5 0–50
Cortisol (nmol/L) 498.6 715.2 367.1 672.0 220–590
DHEA-S (μg/dL) 95.3 – 55.5 – 100–300
Prolactin (mIU/L) 86.6 109.9 43,3 45.9 85–390
*The cortisol level was evaluated at 8.00 am
Fig. 1 a Midline sagittal and b coronal magnetic resonance imaging
(MRI) sections showing hypoplasia of the pituitary anterior lobe and
presence of an anterior lobe cyst in patient 1
Fig. 2 Midline sagittal MRI section showing hypoplasia of the anterior
pituitary lobe in patient 2. The arrow indicates the small pituitary gland
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Hormonal studies
Hormonal assays (Table 1) in both patients showed low serum
GH level that did not rise during insulin-induced
hypoglycaemia and, also, low IGF-1 concentration. The
serum-free thyroxine (fT4) level was low, with TSH concen-
trations below 0.3 mIU/L and poor response during the TRH-
TSH test was evident. Serum LH and FSH levels were unde-
tectable and serum-free testosterone was also very low. Serum
prolactin was low in patient 2 and normal in patient 1, and, in
both cases, only slightly raised in the TRH stimulation test.
Plasma ACTH was in the normal range and serum cortisol
was normal, whereas serum DHEA was below the normal
range.
Genetic analyses
Screening for mutations in CPHD genes revealed a compound
heterozygosity that occurred in both brothers in the PROP1
gene. Two different mutations were identified (c.150delA and
novel c.334C>T transition), and no other significant change in
the reference sequence was present (non-synonymous or rare
polymorphisms were also excluded). With regards to an in-
conspicuous phenotype of the parents and another brother
(they did not give consent for genetic study, although accord-
ing to information provided by the patients, their mother’s
height was 170 cm (0.66 SD), the father’s height was
171 cm (−1.3 SD) and the other brother’s height was
180 cm (0.16 SD); the abbreviated family pedigree is shown
in Fig. 3). We inferred that both alleles carrying mutations
were transmitted independently, confirming the recessive in-
heritance of CPHD. The c.150delA deletion results in a frame-
shift of the coding sequence, starting at codon 53 and further
leading to a premature termination signal at codon 164
(p.R53fsX164). The c.334C>Tsubstitution (Fig. 4) is reported
for the first time and causes an amino acid change of arginine
to the STOP codon (p.R112X) and, therefore, protein trunca-
tion as well. An in silico prediction using MutationTaster2
confirmed significant protein alteration (115 AA missing,
>50 % of the protein sequence) and possible occurrence of
the NMD mechanism. Computation of the PROP1
homeodomain with the use of SWISS-MODEL and Phyre2
revealed the lack of the third, most distally located and longest
alpha helix folding within the DNA-binding homeodomain,
whereas the structure of the two other alpha helices remained
intact (Fig. 5). The mutation screening of POU1F1, LHX3,
LHX4 and HESX1 did not reveal any other concurrent abnor-
malities within coding sequences. The MLPA examination
focusing on the identification of copy number abnormalities
for selected genes did not result in finding any alterations.
Discussion
CPHD caused by PROP1 gene mutation leads to GH, TSH
and gonadotropins deficit, but the course of this disorder may
vary, even within a family with the same genetic defect (Flück
et al. 1998). The diagnosis of GH deficiency usually precedes
those of TSH and LH/FSH, and it happens in more than 80 %
of these patients (Deladoëy et al. 1999; Mody et al. 2002).
Symptoms of central hypothyroidism and mild growth failure
in the first years of life, followed bymarked growth deficiency
and secondary gonadal insufficiency later in life, prevailed in
both of the described patients. Thyroid hormone deficiency
was clinically manifested as oedema of the face, neck and
extremities, and in biochemical evaluation presented as very
low T4 and T3 concentrations and high serum cholesterol.
Secondary testicular failure at and past the age of puberty
was indicated by the lack of any signs of sexual maturation,
no beard or sexual hair growth and infantile genitals with
cryptorchidism in one patient. The hormone assays test
disclosed very low LH, FSH and testosterone concentrations.
Despite a prolonged testosterone replacement therapy, signs of
masculinisation appeared to be of limited extent, as the geni-
tals still remained infantile and there was no beard growth.
This is typical for most patients with CPHD caused by
PROP1 gene defects, but at some points, the clinical manifes-
tation of CPHD in the studied brothers varied. The head cir-
cumferences of both patients reached the 75th and 90th per-
centiles and were typical for 180-cm-tall males, thus differing
from other CPHD cases (Bushby et al. 1992; Rosenbloom
et al. 1999). Lateral and frontal skull radiographs revealed
thick calvarial bones, which may indicate that marked GH
deficiency appeared later. The borderline height of patient 2
in the first two decades of life could also support this expla-
nation. Arroyo et al. (2002) reported a unique case of CPHD
associated with normal height and absent puberty caused by a
PROP1 defect (R120C) also located in the third helix of the
PROP1 homeodomain.
Fig. 3 Abbreviated pedigree of the family with PROP1 gene mutations.
The arrows indicate the individuals examined in this study. Affected
males are denoted by black squares (II:1, II:3), while asymptomatic
obligatory heterozygotes (I:1, I:2) and an individual with unknown
genetic status (II:2) are depicted by question marks
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Hypothyroidism as a first sign is not a frequent finding
in CPHD patients and appears in subjects affected by dif-
ferent genetic defects. Deladoëy et al. reported hypothy-
roidism at 3 years of life in 20 % (7 cases) of the studied
CPHD patients with PROP1 gene mutations (but the par-
ticular PROP1 defects in these cases were not specified)
(Deladoëy et al. 1999). Voutetakis at al. also reported on a
neonate with a novel PROP1 gene mutation (Q83X)
coexisting with previously described 296delGA which led
to protein truncation (the protein product was restricted to
only 82 of the 226 amino acids) and, therefore, absence of
the DNA-binding and transactivation domain of PROP1. A
child affected by these mutations presented prolonged jaun-
dice, early manifested central hypothyroidism and pituitary
enlargement (Voutetakis et al. 2004b). Flück at al. reported
on a girl affected by the R120C PROP1 gene mutation who
presented with a lack of TSH shortly after birth and GH
deficiency gradually appearing with age. The other family
members carrying the same mutation did not present such
course of CPHD, mainly showing severe growth retarda-
tion as a first sign (Flück et al. 1998). The functional stud-
ies of p.R120C substitution done by Wu et al. revealed that
similarly altered mouse Prop1 factor possessed reduced
DNA-binding activity and presented impaired trans-
activation ability (Wu et al. 1998). Two young siblings
under 2 years of age with 296delGA mutation in the
PROP1 gene and isolated central hypothyroidism were also
described by Wassner et al. (2013).
Fig. 4 a Sequence of the second
exon of the PROP1 gene showing
the c.334C>T mutation (position
of nucleotide change is indicated
by an arrow) and b sequence of a
healthy individual as a normal
control
Fig. 5 Modelling of the PROP1 homeodomain (AA 69–128, framed). a
Structural model of the PROP1 homeodomain with depicted position of
112 arginine (arrow). b Prediction of the effect of R112X on the structure,
revealing the lack of the third, longest alpha helix folding. c A string of
the selected region in the PROP1 protein sequence encompassing the
homeodomain (framed) with three alpha-helix folding (shaded) and
marked novel mutation site. The mutations lead to a similar phenotype
p.R99X, c.301-302delAG (p.L102Cfs*8, also referred to as p.S109X)
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The genetic abnormalities found in our reported patients
suggest the lack of a functional protein. Both affected copies
of the PROP1 gene in patients lead to impairment of the main
functional domain of the protein (frameshift, premature termi-
nation signal) and, therefore, production of truncated proteins
with 164 and 112 amino acids residues, respectively. The
pathogenic impact of the known c.150delA mutation has been
well described and evidenced by numerous authors in the
current literature (Fofanova et al. 1998; Riepe et al. 2001;
Turton et al. 2005). Total abrogation of the gene function is
reflected by the reported phenotype of the patients who were
homozygous for the mutation.
The effect of a new change is somehow confusing. The
phenotype of both probands clearly indicates genetic back-
ground, but uncommon manifestation suggests that an allele
carrying the p.R112X change might potentially retain some
residual protein activity. The functional core of the protein
represents a DNA-binding homeodomain located between
amino acids 68 and 130. The p.R112X mutation is placed
directly in the homeodomain region and is terminating protein
synthesis at the beginning of the third alpha helix (Fig. 4).
Based on an in silico prediction of a reference and altered
homeodomain orchestration, we noted that the residual amino
acid sequence of p.R112X is identical to the corresponding
part of the reference protein. The premature termination does
not result in severe remodelling or misfolding of two proximal
alpha helixes and, thus, this protein could potentially maintain
some functionality. Because of the occurrence of a premature
truncation codon at position 112, the NMDmechanism should
also be regarded. However, the milder phenotype of the re-
ported patients compared to carriers of i.e. homozygous
c.150delA change indicates that this mechanism is not effec-
tive and, rather, does not result in substantial degradation of
the abnormal c.334C>T transcript (if it even occurs at all). An
influence of other compensatory genetic or environmental
mechanisms should also be considered, particularly in regards
to other reports presenting a varying range of clinical mani-
festations, depending on the type of mutation (Kelberman and
Dattani 2007; Mody et al. 2002).
The newly discovered alteration of the PROP1 gene is
clinically relevant but the real spectrum of clinical conse-
quences will be unveiled in patients with homozygous state.
Both patients with gene mutations had definite thyroid hor-
mones and probably GH and IGF-1 deficiency, starting in
childhood; although they did not eventually attain a normal
adult height, the presented skull dimensions and facial features
were typical of non-affected adults. This may be explained by
the modifying effect of thyroxine implemented early in the
treatment on GH activity and its effect on bone growth (Do
et al. 2015).
Similar clinical manifestation may appear in various
PROP1 gene defects. This case is addressed to an early central
hypothyroidism as a first symptom in CPHD patients with
different defects: p.R99X(Q), p.R112X and p.S109X
(Tatsumi et al. 2004; Voutetakis et al. 2004b; Wassner et al.
2013). In a substantial portion of CPHD cases, abnormalities
in PROP1 and known CPHD-associated genes have not been
identified. That implies an involvement of new genetic factors
potentially contributing to the regulation of pituitary develop-
ment and functioning, as an interesting target for further stud-
ies to be conducted. Furthermore, the constant improvement
of genetic testing methods, i.e. whole-exome sequencing ap-
proach, that are more broadly employed for routine diagnos-
tics will certainly facilitate the identification of CPHD cases at
an earlier stage, even those with ambiguous course.
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